Crossmark

Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy

Crossref DOI link: https://doi.org/10.1007/s10147-026-03115-x

Published Online: 2026-07-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sasaki, Takeshi

Higashi, Shinichiro

Nishikawa, Kouhei

Iinuma, Koji

Nakane, Keita

Taniguchi, Tomoki

Sano, Yuta

Matsuyama, Aika

Ozawa, Kaori

Tochigi, Kosuke

Tamura, Masataka

Kubota, Yasuaki

Akamatsu, Shusuke

Koie, Takuya

Inoue, Takahiro
Funding

Funding for this research was provided by:

Mie University
License Information

Text and Data Mining valid from 2026-07-11

Version of Record valid from 2026-07-11
More Information

Article History

Received: 20 February 2026

Accepted: 21 June 2026

First Online: 11 July 2026

Declarations

:

: The authors declare no conflicts of interest.

: The protocol for this research project received approval from the appropriately constituted ethics committee of each institution and was conducted in accordance with the provisions of the Declaration of Helsinki (Mie University Hospital Clinical Research Ethics Committee, approval no. H2023-235).

: The requirement for informed consent was waived because this was a retrospective observational study.

: Not applicable.

Document is current

Any future updates will be listed below